Nerviano Medical Sciences signs a license agreement with the American biotechnology company Ignyta for two leading tyrosine kinase inhibitors

Nerviano, 6 November 2013 - Nerviano Medical Sciences (NMS, www.nervianoms.com) has signed a license agreement with Ignyta, Inc. (www.ignyta.com), granting the American biotech company exclusive global development and marketing rights to RXDX-101, a tyrosine kinase inhibitor directed to the TrkA, ROS1 and ALK proteins , which is in clinical development in molecularly defined patient populations for the treatment of solid tumors; and RXDX-102, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, TrkA, TrkB and TrkC, which is currently in preclinical development for the treatment of multiple cancers.
Under the terms of the license agreement, Ignyta will assume sole responsibility for global development and commercialization of RXDX-101 and RXDX-102. Nerviano will be entitled to receive certain upfront and milestone payments, as well as tiered royalty payments on future net sales of RXDX-101 and RXDX-102.

Nerviano Medical Sciences (NMS) is the largest company in Italy, and among the most important in Europe, in the field of research and development in oncology. NMS is already able to boast important cooperation or licensing agreements with pharmaceutical companies such as Genentech (Roche), Pfizer, Novartis and Servier, as well as with biotechnology companies and the world of academia. On 31 December 2011 the Lombardy Region became the major shareholder of NMS, through the FRRB (Regional Foundation for Biomedical Research). For further information on Nerviano Medical Sciences: http://www.nervianoms.com








To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.